secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2021-07-19T23:59:59+00:00
Accession:  0001564590-21-037042
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus CMO Bill Grossman moves to Gilead; Kartik Krishnan takes over clinical development
--------------------------------------------------------------------------------

- Bill Grossman, MD, PhD, resigns as CMO effective July 26, 2021, to become SVP of Oncology Clinical Research at Gilead.
- Grossman will be Arcus's point of contact at Gilead for co-development activities under the alliance.
- Kartik Krishnan, MD, PhD, promoted to lead Arcus clinical development, effective July 26.
- Grossman will provide consulting to Arcus for up to 3 months; his stock option exercise period extended to July 1, 2022.
- Krishnan joined Arcus in 2019 and has been assuming increasing responsibilities since December 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000156459021037042/0001564590-21-037042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000156459021037042/rcus-8k_20210716.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-037042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer